STTK
Shattuck Labs, Inc. Common Stock
stockNASDAQ
shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. compounds derived from shattuck's proprietary agonist redirected checkpoint, arc®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. the company's lead wholly owned program, sl-172154 (sirpα-fc-cd40l), which is designed to block the cd47 immune checkpoint and simultaneously agonize the cd40 pathway, is being evaluated in a phase 1 trial. a second compound, sl-279252 (pd1-fc-ox40l), is being evaluated in a phase 1 trial in collaboration with takeda pharmaceuticals. additionally, the company is advancing a proprietary gamma delta t cell engager, gadlen™, platform, which is designed to bridge gamma delta t cells to tumor antigens for the treatment of patients with cancer. shattuck has offices in both austin, tex
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 6.43 | 2026-09-28 | +4.82% | -5.041 |
| 1M | 6.79 | 2026-09-04 | -0.74% | 0.341 |
| 3M | 7.24 | 2026-07-06 | -6.91% | 1.536 |
| 6M | 6.78 | 2026-04-06 | -0.59% | 1.267 |
| 1Y | 2.35 | 2025-10-03 | +186.81% | 1.361 |
| 2Y | 1.22 | 2024-10-04 | +452.46% | — |
| 5Y | 19.96 | 2021-10-04 | -66.23% | 1.371 |
Shattuck Labs, Inc. Common Stock (NASDAQ:STTK) stock price today is $6.74, and today's volume is 1,843,744. STTK is down 1.462% today. The 30 day average volume is 1.28M. STTK market cap is $676.45M with 100.36M shares outstanding.